Register online | Log in | My Prescrire

Issue contents

• Current issue
• Last 12 issues
• All issues

Topics

• Annual Prescrire Awards
• Advancing healthcare policy
• Positions
• Mediator° - the criminal trial
• Drugs to avoid: 2026 update
• Spotlight

About Prescrire

• Editorial policies
• How we work
• AMP: non-profit
• Financing
• No conflicts of interest
• Where to find us
• About Prescrire International
• Citations in other journals
• A global network

Offers

• Subscribe or renew my subscription
• Solidarity Subscription Rate
• Subscribers: register online
• Prescrire's other products
• Free Special Edition
• Sign up to receive the newsletter

english.prescrire.org

Prescrire's other websites

Prescrire.org Formations Prescrire Prescrire Campus Éviter l'Évitable

In Prescrire's Spotlight

A trustworthy companion  Editorial  With each passing day, it's becoming increasingly difficult to distinguish between reliable information, opinion pieces and blatant disinformation. While this confusing media landscape may not be new, its scale in 2026 is unprecedented, posing a threat to societal stability, democracies around the world and the health of patients. To cut through the confusion, some media sources have opted for a straightforward, tried-and-true method: providing robust information based on verifiable facts. This is the approach Prescrire has taken in the information space for health professionals. Full article available for download (FREE) 1 July 2026

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Elafibranor (Iqirvo°) in primary biliary cholangitis  Marketing Authorisations  Elafibranor has been authorised in the European Union for use in patients with primary biliary cholangitis, either as monotherapy or in combination with ursodeoxycholic acid. Does elafibranor reduce mortality when added to ursodeoxycholic acid in patients with primary biliary cholangitis in whom ursodeoxycholic acid is considered insufficiently effective, or as monotherapy when ursodeoxycholic acid causes unacceptable adverse effects? Does it alleviate symptoms and reduce the incidence of complications? And what are its adverse effects? Full article available for download by subscribers 1 July 2026

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ In-utero exposure to mesalazine: renal disorders, haematological disorders and possibly malformations  Adverse Effects  A group of French regional pharmacovigilance centres analysed several reports of renal disorders in children who had been exposed in utero to mesalazine. Other data on first-trimester exposure suggest a higher risk of major malformations in exposed children than in unexposed children, mainly cardiovascular defects. Full article available for download by subscribers 1 July 2026

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ GLP-1 agonists: thyroid cancer (continued)  Adverse Effects  According to a meta-analysis of 44 randomised clinical trials including a total of 84 000 patients, exposure to a GLP-1 agonist is associated with an approximately 1.6-fold risk of thyroid cancer compared to non-exposure. Full article available for download by subscribers 1 July 2026

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Extending drug shelf life: potential economic and environmental benefits  Outlook  A willingness by pharmaceutical companies to apply to extend the shelf lives of their products could enable savings for national health insurance systems and represent a possible solution to drug shortages. It would also be aligned with a more environmentally-friendly approach. Full article available for download by subscribers 1 July 2026

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Biosimilar drugs: consultation on streamlining their development and evaluation  Advancing Healthcare Policy  In September 2025, Prescrire responded to a consultation by the European Medicines Agency (EMA) on its requirements in relation to the development and evaluation of biosimilars. Full article available for download (FREE) 1 July 2026

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Enjoy these features, and more, in our upcoming issues COMING SOON• Zuranolone in postpartum depression • Omaveloxolone in Friedreich's ataxia • In-utero exposure to paracetamol and neuropsychological development • Compensation for victims of drug-induced harms: new European directive  > Subscribe now 1 July 2026

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ New! "2025 Free Special Edition", from the editors of Prescrire International  FREE SPECIAL EDITION  Check out this selection of articles to introduce you to Prescrire International, a wholly independent monthly drug bulletin, written by and for healthcare professionals. Includes an array of articles from the past year on drugs and health policy in Europe. > Click here for your free copy 1 January 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Subscribe today for full access to top-quality content from Prescrire International  SUBSCRIBE NOW!  Enjoy access to subscriber-only content available on our website, including every article published in Prescrire International since 1992. Prices for a one-year subscription start at 165 euros (less for students and residents of lower-income countries). 1 January 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Follow Prescrire International on LinkedIn and Facebook Keep up with the latest from Prescrire's editors, and support our values of independence and quality information, first and foremost in the interest of patients. Click here to > Follow us on LinkedIn or > Follow us on Facebook 1 January 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Receive the free, monthly "Independent Drug & Healthcare Newsletter" Click here to sign up for the free Newsletter from the editors of the non-profit journal Prescrire International, with highlights of the contents of the latest issue. 1 July 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Drugs to avoid, in the name of better patient care   DRUGS TO AVOID - 2026 UPDATE  Independent French medical journal Prescrire has published its annual update of drugs to avoid. The goal is to make it easier to choose high-quality care, and to prevent disproportionate harm to patients. > Read more

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Read more All the subjects in Prescrire's Spotlight >

• Sitemap |
• Terms of use |
• Contact
• |Top of page

---